Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Ranking Big Pharma's Top Drugs of 2013

By Max Macaluso - Mar 20, 2014 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ranking the pharma industry's three biggest winners of 2013.

In 2012, AbbVie's ( ABBV 0.55% ) Humira brought in $9.3 billion in total sales and was the best selling drug in the world. But did the autoimmune disease drug, which accounts for more than half of AbbVie's sales, keep its crown in 2013?

In the following slideshow, we reveal last year's three best-selling drugs. Blockbusters from powerhouses Amgen ( AMGN 0.96% ), Pfizer ( PFE 1.77% ), Johnson & Johnson ( JNJ 1.38% ), and Merck ( MRK -0.63% ) all made the list.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$74.44 (-0.63%) $0.47
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.68 (1.77%) $0.95
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$158.08 (1.38%) $2.15
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$200.80 (0.96%) $1.92
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$115.91 (0.55%) $0.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.